View : 93 Download: 0

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)

Title
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)
Authors
Lee, Jung-YunPark, Jeong-YeolPark, Sang YoonLee, Jeong-WonKim, Jae WeonKim, Yong BeomJeong, Dae HoonLee, Kwang-BeomKim, Tae-HunLee, In HoChoi, Min ChulKim, Ki HyungKim, Yong-ManLee, Yong JaeKang, SokbomPujade-Lauraine, EricShin, So-JinHong, Dae GyShim, Seung-HyukKim, Yun HwanSong, TaejongBae, JaemanLee, Jong-MinLee, San HuiLee, Eun-JuPark, Sang-IlLee, Sung-JongLee, ChulminLee, Taek SangChang, Suk-JoonKim, Min KyuKGOG Investigators
Ewha Authors
김윤환
SCOPUS Author ID
김윤환scopus
Issue Date
2019
Journal Title
GYNECOLOGIC ONCOLOGY
ISSN
0090-8258JCR Link

1095-6859JCR Link
Citation
GYNECOLOGIC ONCOLOGY vol. 152, no. 1, pp. 61 - 67
Keywords
Ovarian cancerPlatinum-resistantBevacizumabChemotherapyReal world
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Indexed
SCI; SCIE; SCOPUS WOS
Document Type
Article

Proceedings Paper
Abstract
Purpose. To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum resistant ovarian cancer in a real-world setting. Patients and methods. We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. Results. Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade >= 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. Conclusion. In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. (C) 2018 Elsevier Inc. All rights reserved.
DOI
10.1016/j.ygyno.2018.10.031
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE